Feb. 2024

In February, 2024, a 3,000-square-meter clinical drug manufactural facility of Suzhou Fuent Pharmaceutical Co., Ltd. (Qurgen’s China subsidiary) was officially inaugurated. Constructed in accordance with GMP standards, the facility will be employed for the manufacturing of investigational SON-DP transcription factor anti-cancer drug for Phase I, Phase II and Phase III clinical trials conducted by Qurgen and Fuent.